Alamar Biosciences, Inc. - Class A common stock (ALMR)

Alamar Biosciences (NASDAQ:ALMR) reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program, or TAP, services quarter to date. The precision proteomics company also raised its full-year revenue

Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4% to $32.8.

Revenue surged 82% year-over-year to $29.4 million.

Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings call since completing its April initial public offering. Chief

The aggressive growth fund investor was busy adding to some of her established stakes on Monday.